Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RTSN
- Company Retension Pharmaceuticals Inc.
- Price $13.01
- Changes Percentage -6.34
- Change -0.88
- Day Low $12.63
- Day High $13.93
- Year High $11.6
- Year Low $9.66
- Market Cap $39,487,500
- Price Avg 50 EMA (D) $10.77
- Price Avg 200 EMA (D) $10.77
- Exchange NASDAQ
- Volume 788,358
- Average Volume 536,891
- Open $13.92
- Previous Close $13.89
- EPS 0
- PE 0.00
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $3,750,000
Company brief: RETENSION PHARMACEUTICALS INC. (RTSN )
- Healthcare
- Medical - Pharmaceuticals
- Eric L. Keller
- http://www.retensionpharmaceuticals.com
- US
- N/A
- 10-09-2026
- US76135H1005
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
